Surufatinib trial initiated for adjuvant therapy in pancreatic neuroendocrine tumors
A randomized trial is underway to evaluate surufatinib as adjuvant therapy for pancreatic neuroendocrine tumors.
Asset / Drug
Drug and asset intelligence for Surufatinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.